Anti-diabetic effect of anthocyanin cyanidin-3-O-glucoside: data from insulin resistant hepatocyte and diabetic mouse

BACKGROUND

Anthocyanins are a group of natural products widely found in plants. They have been found to alleviate the disorders of glucose metabolism in type 2 diabetes mellitus (T2DM), while the underlying mechanisms remain unclear.

METHODS

HepG2 and L02 cells were incubated with 0.2 mM PA and 30 mM glucose for 24 h to induce IR, and cells treated with 5 mM glucose were used as the control. C57BL/6 J male mice and db/db male mice were fed with a chow diet and gavaged with pure water or cyanidin-3-O-glucoside (C3G) solution (150 mg/kg/day) for 6 weeks.

RESULTS

In this study, the anthocyanin C3G, extracted from red bayberry, was found to alleviate disorders of glucose metabolism, which resulted in increased insulin sensitivity in hepatocytes, and achieved by enhancing the glucose consumption as well as glycogen synthesis in insulin resistance (IR) hepatpcytes. Subsequently, the expression of key proteins involved in IR was detected by western blotting analysis. Protein tyrosine phosphatase-1B (PTP1B), a negative regulator of insulin signaling, could reduce cellular sensitivity to insulin by inhibiting the phosphorylation of insulin receptor substrate-2 (IRS-2). Results of this study showed that C3G inhibited the increase in PTP1B after high glucose and palmitic acid treatment. And this inhibition was accompanied by increased phosphorylation of IRS proteins. Furthermore, the effect of C3G on improving IR in vivo was validated by using a diabetic db/db mouse model.

CONCLUSION

These findings demonstrated that C3G could alleviate IR in vitro and in vivo to increase insulin sensitivity, which may offer a new insight for regulating glucose metabolism during T2DM by using the natural dietary bioactive components. C3G promotes the phosphorylation of IRS-2 proteins by suppressing the expression of PTP1B, and then enhances the sensitivity of hepatocyte to insulin.

Exploring the Effects of Cyanidin-3-O-Glucoside on Type 2 Diabetes Mellitus: Insights into Gut Microbiome Modulation and Potential Antidiabetic Benefits

Berries and their functional components have been put forward as an alternative to pharmacological treatments of type 2 diabetes mellitus (T2DM), and more attention has been paid to the gut microbiome in the pathophysiology of T2DM. Thus, we tried to examine the metabolic impact of red bayberry-derived cyanidin-3-O-glucoside (C3G) and investigate whether the antidiabetic effects of C3G were associated with the gut microbiome. As a result, C3G administration was found to reduce blood glucose levels of diabetic db/db mice, accompanied by increased levels of glucagon-like peptide (GLP-1) and insulin. Moreover, 16S rRNA analysis showed that the dominant microbiota modulated by C3G were pivotal in the glucose metabolism. Furthermore, the modulation of C3G on metabolic activities of gut bacteria leads to an increase in intestinal levels of key metabolites, particularly short-chain fatty acids. This contribution helps in promoting the secretion of GLP-1, which in turn increases insulin release with the purpose of reducing blood glucose levels. Overall, these findings may offer new thoughts concerning C3G against metabolic disorders in T2DM.

Abstract P1-05-27: Evaluation of the Oncomine focus and comprehensive assays for therapeutic stratification in early hormone receptor positive breast cancers

Large-scale sequencing initiatives have revealed a wealth of common and novel variants as well as copy-number aberrations, across different solid tumours and hematological malignancies. The growing list of variants/aberrations can sometimes be matched to specific therapeutics. Such “actionable mutations/changes” hold promise for personalized treatment, as treatments could be tailored to molecular abnormalities, rather than disease site. In breast cancer, women with hormone positive early breast cancer continue to experience improved survival on adjuvant anti-hormone therapy, but even today, a significant number of women continue to progress. Therefore there is not only a need to identify those women for whom current therapies are insufficient, but to identify alternative therapeutic interventions. The ThermoFisher Scientific Oncomine™ Focus and Oncomine™ Comprehensive Assays (OFA and OCA) are based on the Ion Torrent™ next-generation sequencing platform and Ion AmpliSeq™ library preparation technology, coupled to the Oncomine™ Knowledgebase, for target selection, variant calling, and data annotations. Both panels interrogate the most referenced oncology biomarker variants that are matched to curated published evidence from clinical trials supporting the matching of driver genetic variants with relevant potential clinical therapeutic options. The ability to identify SNVs, CNVs and fusion events in a single assay provides an unprecedented approach to maximizing the molecular information to be derived from a single tumour sample. To explore the value of the Oncomine™ assays in early invasive breast cancers, we have performed a pilot study to assess the reproducibility and accuracy of the OFA and OCA from nucleic acids extracted from formalin-fixed paraffin embedded tissues. In addition to the sequencing and copy-number data generated by these assays, we will compare these results to copy-number information generated using the Oncoscan® (Affymetrix)copy-number assay as well as information derived by Multiplex Ligation-dependent Probe Amplification-based panels (MRC-Holland) and Fluorescent in situ Hybridization (FISH). Our preliminary analyses of 35 invasive breast cancers by Oncoscan® identified the frequent whole chromosomal gains of 2, 3, 5, 7, 18, 19 and 20; gains of 1q, 7p, 8q, 11p, 16p, 17q; losses at 1p, 8p, 11q, 13, 16q, 17p and chromosome 18. High level amplifications were also identified for breast cancer related genes such as ERBB2, CCND1, MYC, FGFR1; in addition to the frequent losses of TP53, RB1, CDKN2A. Copy-number changes were confirmed by locus-specific FISH and MLPA. Data generated from the OFA and OCA from these same samples will be compared to the other platform findings and provide a snapshot of the mutational landscape of early breast cancers across these pan-cancer panels. Having established the robustness and accuracy of the assays, the applicability of the OCA in the context of improved stratification for breast cancers for prognostic and predictive tests will be discussed.

Citation Format: Bayani J, Crozier C, Zhang NX, Amemiya Y, Quintayo MA, Yan FJ, Dion D, Mccormack S, Yaffe M, Seth A, Feilotter H, Bartlett JMS. Evaluation of the Oncomine focus and comprehensive assays for therapeutic stratification in early hormone receptor positive breast cancers [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-05-27.

Abstract P1-07-17: V Array: A novel tool for constructing virtual tissue microarrays (TMAs), an evaluation of its use in optimizing TMA construction for Ductal Carcinoma in Situ (DCIS)

Introduction: The use of TMAs has become invaluable in the assessment of large patient cohorts in clinical practice. TMAs facilitate high throughput analysis and increase biomarker standardization. However, there is little evidence in the literature validating the number of cores required to be representative of the whole tumor. With increasing evidence indicating the heterogeneous nature of many tumors such evidence is critical.

DCIS is becoming an increasingly common diagnosis with 5000 new cases p.a. in Canada; with women at risk of recurrence and invasion. It is challenging to create TMAs for DCIS in view of the scattered distribution of the involved ducts. Furthermore, ducts affected with DCIS often vary in architecture, nuclear grade and presence of comedo necrosis even within individual patients. This study aims to determine the number of cores required to construct representative TMAs for different biomarkers in the setting of DCIS.

Materials and Methods: Tumor blocks from 102 patients presenting with DCIS alone were retrieved from the archives of Sunnybrook Hospital. Sequential tissue sections were stained with H&E, ER, PgR, HER2 and Ki67. All slides were manually evaluated and Histo-scores determined for ER, and PR, % positive cells for Ki67. and HER2 was classified in accordance with the 2007 ASCO/CAP guidelines. Slides were then scanned at x1.25 magnification on the Ariol SL50 Image Analysis system (Leica Microsystems). A map representing a 5 × 2 TMA, with 0.6mm2 cores was placed on the scanned image of the H&E stained slides and 10 regions of interest (ROI) identified (where possible). The H&E and IHC were then slide linked to then allow identification of the same ROI. The slides were then rescanned on x20, this time only the mapped areas were scanned creating virtual “TMA cores”. Using the V Array (virtual array) function within the Ariol software the virtual cores were placed in a V Array. Previously validated algorithms for ER, PR, HER2 and Ki67 were used to directly analyze each core and the results exported to Excel for analysis. The continuous mean was assessed for increasing numbers of cores and used to determine the optimal number of cores required to be representative of the whole tumor.

Results: Virtual TMAs were successfully constructed on all cases. The Histo score of increasing numbers of cores was determined and compared to the overall Histo score for the tumor. The mean numbers of cores required to be representative of the whole tumor was three.

Discussion: V array proved an excellent tool for the creation of virtual TMAs and helped to identify the minimum number of cores required to be representative. This technology also has wider applications and may prove very useful in the evaluation of samples with insufficient tumor to allow physical cores to be taken, or where tumors are rare. With the increase in digital pathology and access to scanned images V array will be a valuable addition as a research tool.

Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-07-17.